

AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in the application.

1. (Previously presented) An immunogenic complex, comprising a negatively-charged organic complex and a positively-charged antigen, where (A) said organic complex comprises a saponin and a sterol and (B) said organic complex and antigen are associated by an electrostatic interaction, wherein said organic complex is a naturally negatively charged complex, which has been modified to increase the degree of its negative charge, and said antigen is a naturally positively charged antigen, which has been modified to increase the degree of its positive charge.
2. (Canceled)
3. (Previously presented) The immunogenic complex according to claim 1 wherein said antigen is a protein or comprises a peptide region.
- 4-11. (Canceled)
12. (Previously presented) The immunogenic complex according to claim 1 wherein the organic complex further comprises a phospholipid.
13. (Previously presented) The immunogenic complex according to claim 12 wherein said phospholipid is a phosphoglyceride.
14. (Previously presented) The immunogenic complex according to claim 13 wherein the phosphoglyceride is selected from the group consisting of phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid and cardiolipin.
15. (Previously presented) The immunogenic complex according to claim 12 wherein said phospholipid is lipid A.
16. (Previously presented) The immunogenic complex according to claim 15 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A and monophosphoryl lipid A.

17. (Previously presented) The immunogenic complex according to claim 1, wherein said immunogenic complex induces a cytotoxic T-lymphocyte response when administered to a mammal.

18-52. (Canceled)

53. (Previously presented) An immunogenic complex comprising a negatively-charged organic complex and a positively-charged antigen, where (A) said organic complex and said antigen are associated by an electrostatic interaction and (B) said complex generates a cytotoxic CTL response when administered to a mammal, wherein (i) the organic complex comprises a saponin and a sterol, and (ii) the organic complex is modified to increase the degree of its negative charge and/or the antigen is modified to increase the degree of its positive charge.

54. (Previously presented) An immunogenic complex, comprising a negatively-charged organic complex and a positively-charged antigen, where (A) said organic complex comprises a saponin and a sterol and (B) said organic complex and antigen are associated by an electrostatic interaction, wherein said organic complex is a naturally negatively charged complex which has been modified to increase the degree of its negative charge.

55. (Previously presented) An immunogenic complex, comprising a negatively-charged organic complex and a positively-charged antigen, where (A) said organic complex comprises a saponin and a sterol and (B) said organic complex and antigen are associated by an electrostatic interaction, wherein said antigen is a naturally positively charged antigen which has been modified to increase the degree of its positive charge.